BMO Capital Markets Increases Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target to $35.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price lifted by analysts at BMO Capital Markets from $20.00 to $35.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 114.99% from the stock’s previous close.

CNTA has been the topic of a number of other reports. Jefferies Financial Group raised their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Morgan Stanley raised their target price on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Friday, June 21st. Guggenheim lifted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, Oppenheimer restated an “outperform” rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.60.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $16.28 on Monday. The company has a market cap of $1.64 billion, a PE ratio of -11.46 and a beta of 1.44. The company has a fifty day moving average price of $12.04 and a two-hundred day moving average price of $10.56. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. Centessa Pharmaceuticals has a 12 month low of $5.15 and a 12 month high of $17.59.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Research analysts expect that Centessa Pharmaceuticals will post -1.61 earnings per share for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total value of $148,449.66. Following the sale, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total value of $148,449.66. Following the sale, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Saurabh Saha sold 4,169 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the sale, the chief executive officer now owns 827,755 shares in the company, valued at $10,197,941.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 216,873 shares of company stock worth $3,472,000. 11.59% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently bought and sold shares of CNTA. Jump Financial LLC purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth about $114,000. Trexquant Investment LP purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth about $114,000. Franklin Resources Inc. increased its stake in Centessa Pharmaceuticals by 34.1% in the 4th quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock worth $8,882,000 after purchasing an additional 283,469 shares in the last quarter. Platinum Investment Management Ltd. increased its stake in Centessa Pharmaceuticals by 12.9% in the 4th quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock worth $3,033,000 after purchasing an additional 43,539 shares in the last quarter. Finally, Octagon Capital Advisors LP increased its stake in Centessa Pharmaceuticals by 333.2% in the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock worth $16,398,000 after purchasing an additional 1,584,500 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.